A Wisconsin medical device startup developing less invasive methods for cancer patients and others requiring long-term intravenous treatment is trying to raise $1.5 million, according to a regulatory filing.
Stealth Therapeutics‘ Invisiport device — what it calls a micro-invasive implantable arm port — offers a less invasive alternative to chest ports, which require complex surgical procedures that have their own risk of complications. Further, chest ports are easily visible and often lead to scarring. By contrast, the Invisiport can be inserted just like PICC (peripherally inserted central catheter) lines but offers benefits that PICC lines don’t, according to the company’s website.
Why Workflow Chaos Is Undermining Care – and What Providers Can Do About It.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
The company was founded in 2006 by Dr. Bradley Glenn, a practicing interventional radiologist. Stealth Therapeutics’ CEO is Peter Drumm, formerly the general manager at JT Packard and Associates, a backup power service and supply company. Board members are Jake Orville, CEO of Prognostix, which markets a technology developed at the Cleveland Clinic to diagnose cardiovascular disease; and George Trutza, president and CEO of Impliant, a spine disorder treatment company.
A call to the company was not immediately returned.
[Photo Credit: 89studio]